AGRX AGILE THERAPEUTICS

Agile Therapeutics Launches I’m So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control

Agile Therapeutics Launches I’m So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control

Visit  to learn more about some of the many available contraceptive options

  • I’m So Done is a national unbranded campaign intended to enhance the birth control conversation for women
  • Encourage education on contraceptive care options
  • Facilitate an honest discussion between women and their healthcare providers  
  • Spark a social community of likeminded women in the “So Done Club,” reassuring them that they are not alone
  • Join the conversation by participating on social media platforms, including the @SoDoneClub  and  pages

PRINCETON, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the launch of I’m So Done, an education and empowerment platform that encourages women to think about their current contraceptive method and decision-making journey.

"We are excited to launch I’m So Done, a new digital-first campaign to help women recognize that they have the right to be an active participant in selecting contraceptive care that suits their lifestyle,” said Al Altomari, Chairman and Chief Executive Officer of Agile Therapeutics.

Agile Therapeutics Vice President of Marketing Amy Welsh added, “We believe that finding the right contraceptive method is an important factor in sexual and reproductive health. Yet, despite the availability of a wide range of birth control options, many women struggle to determine which method is the best fit for them. I’m So Done will provide education and encouragement for women to take a more empowered and informed role in shared decision-making with her healthcare provider about birth control.”

I’m So Done features a balanced discussion of the spectrum of contraceptive methods, helping women to explore their options. The campaign is designed to encourage a two-way dialogue between women and their healthcare providers about sexual health as well as contraceptive practices and concerns. In addition to education, I’m So Done provides a safe place for women to discuss their experiences, with the reassurance that they are not alone, on the @SoDoneClub  and  pages.

“Women stay on a method longer if it is a method of their choosing and contraceptive education is critical to informing choice,” said Deborah Arrindell, VP of Health Policy at the American Sexual Health Association. “According to the Guttmacher Institute, a woman who wants two children will use contraception for about three decades. Women need different options throughout their lives, and we welcome a platform like I’m So Done to help women learn about contraceptive choice for their lifestyle.”

Visit to see how real women are responding to a poll about birth control, and to find helpful information and tools outlining the pros and cons of various contraceptive methods. 

About Agile Therapeutics, Inc.

Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at . The Company may occasionally disseminate material, nonpublic information on the Company’s website.

Follow Agile on  and Twitter: .

Source: Agile Therapeutics

Contact: 

Matt Riley

Head of Investor Relations & Corporate Communications

 

Photos accompanying this announcement are available at:

EN
02/09/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AGILE THERAPEUTICS

 PRESS RELEASE

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud P...

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L. Agile Therapeutics has combined with Insud Pharma’s US Subsidiary, Exeltis USA, Inc., expanding an already significant women’s health/contraceptive portfolio Agile Therapeutics Common Shareholders to receive $1.52 per share of common stock Agile common stock will cease to be listed on the OTC QB PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (“Agile”) (OTCQB: AGRX), a women's healthcare company, today announced the completion of the acquisition of Agile by Insud Pharma, S.L. ...

 PRESS RELEASE

Agile Therapeutics Inc. Announces Definitive Merger Agreement with Ins...

Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L. Agile Therapeutics will combine with Insud Pharma’s US Subsidiary, Exeltis, expanding an already significant Women’s Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to receive $1.52 per share of common stock – approximately a 356% premium to the closing share price on June 25, 2024 Definitive Merger Agreement is subject to Agile Shareholder Approval. Agile Board is recommending shareholder approval of the Definitive Merger Agreement PRINCETON, N.J., June 26, 2024 (GLOBE...

 PRESS RELEASE

Agile Therapeutics Reports First Quarter 2024 Financial Results and Pr...

Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. “We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sa...

 PRESS RELEASE

Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial R...

Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pi...

 PRESS RELEASE

Agile Therapeutics Announces Delisting from Nasdaq

Agile Therapeutics Announces Delisting from Nasdaq PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company has received a final delisting notice from Nasdaq. The delisting is a result of failure to regain compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch